BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30927677)

  • 21. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Schmitt A; Feldmann G; Zander T; Reinhardt HC
    Oncol Res Treat; 2018; 41(10):619-625. PubMed ID: 30286473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in Systemic Therapy in Pancreatic Cancer.
    Yu KH
    Hematol Oncol Clin North Am; 2024 Jun; 38(3):617-627. PubMed ID: 38575456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
    Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
    J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
    Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic ductal adenocarcinoma in the era of precision medicine.
    Zheng-Lin B; O'Reilly EM
    Semin Oncol; 2021 Feb; 48(1):19-33. PubMed ID: 33637355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
    Aguirre AJ; Nowak JA; Camarda ND; Moffitt RA; Ghazani AA; Hazar-Rethinam M; Raghavan S; Kim J; Brais LK; Ragon D; Welch MW; Reilly E; McCabe D; Marini L; Anderka K; Helvie K; Oliver N; Babic A; Da Silva A; Nadres B; Van Seventer EE; Shahzade HA; St Pierre JP; Burke KP; Clancy T; Cleary JM; Doyle LA; Jajoo K; McCleary NJ; Meyerhardt JA; Murphy JE; Ng K; Patel AK; Perez K; Rosenthal MH; Rubinson DA; Ryou M; Shapiro GI; Sicinska E; Silverman SG; Nagy RJ; Lanman RB; Knoerzer D; Welsch DJ; Yurgelun MB; Fuchs CS; Garraway LA; Getz G; Hornick JL; Johnson BE; Kulke MH; Mayer RJ; Miller JW; Shyn PB; Tuveson DA; Wagle N; Yeh JJ; Hahn WC; Corcoran RB; Carter SL; Wolpin BM
    Cancer Discov; 2018 Sep; 8(9):1096-1111. PubMed ID: 29903880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
    Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
    Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
    J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA mutations in pancreatic cancer and progress in their targeting.
    Alkassis S; Yazdanpanah O; Philip PA
    Expert Opin Ther Targets; 2021 Jul; 25(7):547-557. PubMed ID: 34289788
    [No Abstract]   [Full Text] [Related]  

  • 30. Changing the course of pancreatic cancer--Focus on recent translational advances.
    Javle M; Golan T; Maitra A
    Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma.
    Golan T; Hammel P
    J Natl Compr Canc Netw; 2021 Apr; 19(4):469-473. PubMed ID: 33845459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
    Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.
    Luchini C; Brosens LAA; Wood LD; Chatterjee D; Shin JI; Sciammarella C; Fiadone G; Malleo G; Salvia R; Kryklyva V; Piredda ML; Cheng L; Lawlor RT; Adsay V; Scarpa A
    Gut; 2021 Jan; 70(1):148-156. PubMed ID: 32350089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
    Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
    Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.
    Armstrong SA; Schultz CW; Azimi-Sadjadi A; Brody JR; Pishvaian MJ
    Mol Cancer Ther; 2019 Nov; 18(11):1899-1908. PubMed ID: 31676541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation therapies for pancreatic cancer.
    Buckley CW; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
    Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-derived xenograft models of BRCA-associated pancreatic cancers.
    Golan T; Atias D; Stossel C; Raitses-Gurevich M
    Adv Drug Deliv Rev; 2021 Apr; 171():257-265. PubMed ID: 33617901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.